Neurocrine Biosciences announced that it will lay off approximately 130 employees at its San Diego campus, as a part of its restructuring program to prioritize its R&D programs and associated costs and expenses after an FDA delay on insomnia treatment indiplon. Following the firings, Neurocrine will have approximately 120 employees. One Dec. 13, the FDA issued Neurocrine an “approvable letter” for indiplon, requesting additional clinical and preclinical data on the drug before...